The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://myatelr779000.plpwiki.com/7290728/retatrutide_vs_tirzepatide_a_comparative_analysis